Unusual pulmonary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: Comparison with endoperoxides and other prostanoids ( Contributed by Josef Fried, September 12, 1977 ABSTRACT Microsomes from stomach fundus and blood vessels transform the endoperoxide, PGH2, into a newly discovered unstable substance, PGI2, that relaxes arterial stri4s and inhibits platelet aggregation. 13,14-Dehydro-PGI2 methyl ester, a newly synthesized, stable PGI2 analog, was found to have potent vasodilator activity in the feline and simian pulmonary vascular bed. The PGI2 analog decreased lobar arterial perfusion pressure in the intact cat and monkey. Because pulmonary blood flow was held constant and left atrial pressure was unchanged, the decrease in perfusion pressure reflects a decrease in pulmonary vascular resistance. The dilator response was unusual in that it persisted for 10-12 min, whereas the response to PGEI, the only other vasodilator prostaglandin in the mature animal, persisted for only 1-2 min. The dilator response to the PGI2 analog was enhanced when pulmonary vascular resistance was increased. This substance had less effect on cardiac output and aortic pressure than PGEI, whereas it was a more potent pulmonary vasodilator. These data demonstrate that prostacyclin-like substances possess novel vasodilator activity in the pulmonary circulation and suggest a therapeutic use in the treatment of pulmonary hypertensive diseases.
The biosynthesis of prostaglandins (PGs) E2 and F2a from arachidonate by homogenates of guinea pig lung was first described in 1965 (1) . In the initial step in the biosynthetic pathway, arachidonate is transformed by a microsomal cyclo-oxygenase into the unstable cyclic endoperoxides PGG2 and PGH2 (2) (3) (4) . The endoperoxides are then converted by specific terminal enzymes into primary PGs, thromboxanes, or a newly discovered metabolite, PGI2 (prostacyclin) (5) (6) (7) (8) (9) (10) . PGI2, a labile substance, is a potent inhibitor of platelet aggregation and relaxes arterial smooth muscle strips (11) . The half-life of PGI2 in Tris buffer at pH 7.6 is about 10 min (12) . Recently, the synthesis of a stable PGI2 analog, 13,14-dehydro-PGI2 methyl ester ( Fig. 1 ), which has a half-life of more than 24 hr under the same conditions, has been described (13) . This substance, like authentic PGI2, was found to be a potent inhibitor of platelet aggregation (13) . The PGI2 analog was also found to be a potent vasodilator with activity equal to that of PGE2 in the feline intestinal vascular bed (14) .
The purpose of the present study was to investigate the effects of this substance on the monkey and feline pulmonary vascular bed, using a newly described technique to maintain pulmonary blood flow constant in the intact animal. In addition, the effects of PGI2 analog, arachidonic acid, PGH2, and PGE1 on the pulmonary circulation were compared. Our results show that the PGI2 analog has unusual vasodilator activity in the feline and simian pulmonary vascular beds.
METHODS AND MATERIALS
The technique for controlled perfusion of a vascularly isolated lung lobe in the intact dog has been described in detail (15) and has been used in large animals such as swine and lamb (16, 17) .
This method was modified to permit studies in smaller animals, with the relatively small quantities of PGI2 analog and PGH2 available. Forty-eight adult cats (2.6-3.5 kg) and 10 monkeys (Macaca isis) (3.9-8.1 kg), unselected as to sex, were anesthetized with pentobarbital sodium (35 mg/kg) and strapped in the supine position on a fluoroscopic table. They breathed spontaneously through pediatric endotracheal tubes. A specially designed 6-F triple-lumen balloon perfusion catheter was passed with fluoroscopy pervenously into the artery to the left lower lobe. After the lobar artery was vascularly isolated by balloon distention, it was pump perfused with heparinized femoral arterial blood through the catheter lumen immediately beyond the balloon. Lobar arterial pressure was measured through the third lumen, 5 mm distal to the perfusion port on the perfusion catheter. Left atrial pressure was measured through a transseptally placed 4-F Teflon catheter. Cardiac output was determined by thermodilution (injection of 2 ml of 5% dextrose into the left atrium and computation of blood flow by detecting temperature changes with a 2-F thermistor catheter in the ascending aorta).
The perfusion rate to the lobe was adjusted so that arterial pressure in the perfused lobe approximated the pressure in the main pulmonary artery and was maintained at this rate throughout the experiment. Flow rates were 30-50 ml/min in cats and 45-48 ml/min in monkeys. During in ventilated and nonventilated lobes in a random manner, with reported methods (19) .
PGI2 analog was prepared by methods recently described (13) . The analog was taken up in absolute ethanol (0.4-1 ml), diluted to concentrations of 100, 10, and 1 ,ug/ml in isotonic saline, and stored in a freezer. PGH2 was prepared and purified essentially as described (3, 4) and stored at -700 in dry acetone at a concentration of 1 Mug/Mil. Aliquots were prepared in cool saline immediately before administration. Injections were made through the saline-filled distal catheter lumen directly into the lobar artery, so that exposure of PGH2 to circulating blood was minimal. The vehicles, ethanol or acetone at >0.01%, had no effect on the pulmonary vascular bed. The preparation (20) and use of the two PGH2 analogs, (15S)-hydroxy-lla,9a-epoxymethanoprosta-5Z,13E-dienoic acid (11a,9a-analog, II) (21) and (15S )-hydroxy-9a, 1 la-epoxymethanoprosta-5Z, 13E-dienoic acid (9a,IIa-analog, III) ( Fig. 1 ) (22) , the use of arachidonic acid (5, 8, 11, 14 , eicosatetraenoic acid, Nuchek Prep 99%) (21), PGE1 (Upjohn) (16) and meclofenamic acid (Parke, Davis) (21) have been described. The volume of injected solutions was always less than 0.35 ml. Data were analyzed by methods described by Snedecor and Cochran (23) for paired and grouped data. The values were expressed as mean ± SEM and a P value <0.05 was considered significant.
RESULTS
With pulmonary vascular resistance at resting levels, intralobar injection of PGI2 analog (3.0 ,ug) decreased lobar arterial pressure in four cats (Fig. 2) . The response appeared in 20-25 sec. with the maximum pressure drop at 5-7 min, and returned to control level at 10-12 min. The response to the PGI2 analog was further studied under conditions of increased pulmonary vascular resistance. Continuous intralobar infusion of the 11a,9a-analog ng/min; 8-15 min) increased lobar arterial pressure (from 15.5 :i 1 mm of Hg to 38.5 + 1.8 mm of Hg) but did not affect left atrial pressure. After lobar arterial pressure had stabilized at the higher level, bolus injection of PGI2 analog (0.3-3 Mig) also decreased lobar arterial pressure.
The response was again prolonged and dose-related. However, when vascular resistance was increased, the depressor response to 0.3 14g of PGI2 analog was greater than that observed with 3.0 ,gg of that substance during the control period. Furthermore, during continuous infusions of the 1lla,9a-analog, injection of 3.0 MAg of PGI2 analog caused a marked decrease in pressure at 0.5 min, and pressure decreased even more at 6 min. Lobar arterial pressure returned to or near preinjection level in [10] [11] [12] min. Responses to the PGI2 analog were compared under similar conditions in six other cats with those to PGE1, the only known pulmonary vasodilator in mature animals. Intralobar injection of 3.0 ,g of PGE1 decreased lobar arterial pressure.
The depressor response appeared in 30 sec and was over in 1-2 min. After perfusion pressure was increased (from 14.8 + 1.0 mm of Hg to 39 + 1.3 mm of Hg) by continuous infusion of the ll1a,9a-analog, intralobar injection of PGE1 produced a dosedependent dilator response. In these experiments, the depressor response to PGE1 was over in 1-2 min. At the maximum, the depressor response to the PGI2 analog was significantly greater than that to PGE1 at each dose level studied.
The effects of PGI2 analog on the simian pulmonary vascular PGE,.,,ug In contrast, all other prostanoids studied increased the lobar arterial pressure. Bolus intralobar injection of PGH2 in the cat rapidly increased lobar arterial pressure with the response peaking at 6-8 sec and disappearing in 15-20 sec (Fig. 4) . The stable lla,9a-analog was more than 100 times as potent as PGH2, and the 9a,11a-analog was approximately 100 times as potent. Pressor responses to the two PGH2 analogs were also rapid in onset but longer in duration than the response to PGH2. The pressor response to 3 Atg of PGH2 was approximately equal to that to 10 jig of arachidonic acid (Fig. 5) . Pressor responses to these agents were also compared in the monkey (Figs. 6 and  7) . In this species, the lla, 9a-analog was 10 Perfusion of the feline pulmonary vascular bed with saline instead of blood did not significantly change the pressor response to the lla,9a-analog or PGH2 in two cats, but the response to arachidonic acid was increased by a factor of 10 (Fig.  8) . Similar responses were observed in one monkey during saline perfusion. Administration of sodium meclofenamate (2.5 mg/kg intravenously) in four cats did not significantly alter the pressor response to PGH2 (Fig. 4) or to the 1a,9a-analog (30 ng) but attenuated the pressor response to arachidonic acid (Fig.  5) . In three cats, pressor responses to PGH2 (3 gig), the ll1a,9a-analog (30 ng), and arachidonic acid (30 ng) were not different in ventilated and nonventilated lungs. Similar observations were made in one monkey. Left atrial pressure was unchanged in all these experiments.
DISCUSSION
Results of the present study show that PGI2 analog decreases lobar arterial pressure in the intact cat and monkey. Inasmuch as pulmonary blood flow was maintained constant and left atrial pressure was unchanged, the decrease in pressure indicates that the analog dilates the pulmonary vascular bed. The pattern of the response was unusual in that pressure decreased gradually over 5-7 min and then returned slowly to control value over 10-12 min. In contrast to the unusually prolonged response to this compound, the depressor response to PGEI appeared rapidly and persisted for only 1-2 min. The reason for the prolonged response to the PGI2 analog is uncertain but may suggest that the analog is metabolized slowly in the lung. Both substances decreased aortic pressure, with PGE1 being slightly more potent. Cardiac output was increased by PGE1 but not by the PGI2 analog.
Although the magnitude of the depressor response to the PGI2 analog was rather small under resting conditions in the intact cat and monkey, it was marked when pulmonary vascular resistance was increased by infusion of lla,9a-analog (Fig. 1) , a potent pulmonary vasoconstrictor in these species. The va- sodilator response to the PGI2 analog in the lung is unlikely to be related to an inhibition of platelet aggregation induced by the PGH2 analogs because the pressor response to these substances was independent of formed elements in the blood.
Although PGI2 analog caused dilation of the pulmonary vascular bed, both PG precursors arachidonic acid and endoperoxide PGH2 were constrictors in the pulmonary vascular bed. Moreover, the stable ll1a,9a-and 9alla-analogs, which biologically mimic thromboxane A2 (24) , likewise had striking vasoconstrictor activity in the intact cat and monkey. These data indicate that, under physiologic conditions, the predominant products formed from arachidonate and PGH2 in the lung are vasoconstrictors. Yet, the pathways of PG metabolism that revolve around the pivotal intermediate PGH2 can produce vasoconstrictor products, such as primary PGs and thromboxanes, as well as a vasodilator such as PGI2. It is therefore possible that the nature of the enzymes involved in the transformations of PGH2 to vasoactive metabolites (PGs, thromboxanes, prostacyclins) and their regulation may serve to control resistance to blood flow in the lung and thereby regulate ventilation-perfusion relationships.
Although endoperoxides and their analogs have been reported to increase bronchomotor tone, the contribution by changes in airway smooth muscle tone appears to be small because similar responses were obtained in ventilated and nonventilated lungs. Furthermore, although in vitro studies have shown that PGH2 and arachidonic acid have marked platelet aggregating activity in some species (3, 4, 25) , mechanical obstruction with platelet aggregates probably contributed little to the response in the intact cat: the responses to PGH2 and to the PGH2 analogs were similar during perfusion with blood or saline. The pressor response to arachidonic acid in this species is also not platelet dependent because the response to the precursor was enhanced during the saline perfusion. The greatly enhanced response to arachidonic acid during saline perfusion probably results from the absence of protein binding (26 (22) . The difference may reflect in part the extremely short half-life of PGH2 in the body. The vasoactive metabolites of PGH2 include thromboxane A2, PGI2, PGE2, and PGF2a, and it has been reported that the major cyclo-oxygenase products formed when arachidonate was infused into the isolated guinea pig lung were thromboxane B2, the metabolite of thromboxane A2, and (12L)-hydroxy-5,8,10-hepadecatrienoic acid, a breakdown product of PGH2, with very small amounts of PGF2a and PGE2 (27) . The relative contribution of PGH2 itself and its rapidly formed vasoactive metabolites to the modest pulmonary vasoconstrictor response to exogenous PGH2 in intact animals is unknown. However, the present experiments direct attention to the possibility that PGI2, which appears to be qualitatively and quantitatively similar to 13,14-dehydro-PGI2 (13, 14) , may also be produced from PGH2 in the intact lung in sufficient quantity to attenuate the vasoconstrictor response produced by PGH2 and its metabolites. Similarly, PGI2 may contribute to the systemic vasodilation produced by the cyclo-oxygenase products of arachidonic acid (21) . Finally, the potent and prolonged pulmonary vasodilator effect of PGI2 analog, as shown by the complete reversal of the intense vasoconstrictor response to continuous infusion of the 11a,9a analog for 4-6 min with a single 3-,Mg bolus injection, suggests that this agent may have therapeutic potential in selected patients with pulmonary hypertensive diseases. Additionally, the ability of the PGI2 analog to inhibit human platelet aggregation (9-11) suggests therapeutic potential in patients with thromboembolic diseases.
